Antidepressant Effects of Cleistocalyx nervosum Extract Consumption in a Rat Model of Post Stroke Depression
Abstract
The aim of this study was designed to evaluate whether Cleistocalyx nervosum (C. nervosum) extract improved depression-like behaviors induced by middle cerebral artery occlusion (MCAO) in post-stroke-depression (PSD) rats. Right MCAO procedure was performed on day 1 in male Wistar rats. C. nervosum was thereafter administered (250, 500 and 750 mg/kg), daily for 28 days. Neurological functions after ischemia were determined by the forelimb grip force and the hot plate tests. Tail suspension (TST) and forced swimming (FST) tests were used to assess depression-like symptoms. Plasma corticosterone (CORT) level, and brain oxidative status, and scavenging enzymes were also investigated. Our results showed that three doses of C. nervosum treatment were able to diminish neurological impairments and exert antidepressant effects in PSD rats. This was accompanied by the decrease in stress hormone level and brain oxidation indices, and increase in antioxidant enzymes activities. It suggested that C. nervosum could improve the depression-like emotional status and promote recovery of motor and sensory functions in PSD, and can be applied as a complementary agent for treatment of PSD.
Full Text:
PDFReferences
Robinson RG, Jorge RE. Post-stroke depression: a review. Am J
Psychiatry. 2016; 173: 221–31
Ayerbe L, Ayis S, Crichton SL, Rudd AG, Wolfe CD. Explanatory
factors for the increased mortality of stroke patients with
depression. Neurology. 2014; 83: 2007–12.
Nabavi SF, Dean OM, Turner A, Sureda A, Daglia M, Nabavi SM.
Oxidative stress and post-stroke depression: possible therapeutic
role of polyphenols? Curr Med Chem. 2014; 22: 2014.
Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S.
Major depressive disorder is accompanied with oxidative stress:
short-term antidepressant treatment does not alter oxidative–
antioxidative systems. Hum Psychopharmacol. 2007; 22: 67- 73.
Galecki P, Florkowski A, Bobinska K, migielski J, Bienkiewicz M,
Szemraj J. Functional polymorphism of the myeloperoxidase
gene (G-463A) in depressive patients. Acta Neuropsychiatr. 2010;
: 218-22.
Galecki P, Smigielski J, Florkowski A, Bobinska K, Pietras T,
Szemraj J. Analysis of two polymorphisms of the manganese
superoxide dismutase gene (Ile-58Thr and Ala-9Val) in patients
with recurrent depressive disorder. Psychiatry Res. 2010; 179: 43-
Du X, Pang TY. Is Dysregulation of the HPA-Axis a Core
Pathophysiology Mediating Co-Morbid Depression in
Neurodegenerative Diseases? Front Psychiatry. 2015; 6: 32.
Bhagwagar Z, Hafizi S, and Cowen PJ. Increased salivary cortisol
after waking in depression. Psychopharmacol. 2005; 182: 54–7.
Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in
the treatment of depression: can we think outside the endocrine
hypothalamus? Depress Anxiety. 2009; 26: 641–9.
Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than
St. John's Wort, in the treatment of depression: a systematic
review. Altern Med Rev. 2011; 16: 40–9.
Muller LG, Salles LA, Stein AC, Betti AH, Sakamoto S, Cassel E, et
al. Antidepressant-like effect of Valeriana glechomifolia Meyer
(Valerianaceae) in mice. Prog Neuropsychopharmacol Biol
Psychiatry. 2012; 36: 101–9.
Taya S, Punvittayagul C, Inboot W, Fukushima S,
Wongpoomchai R. Cleistocalyx nervosum extract ameliorates
chemical-induced oxidative stress in early stages of rat
hepatocarcinogenesis. Asian Pac J Cancer Prev. 2014; 15: 2825-
Charoensin S, Taya S, Wongpornchai S, Wongpoomchai R.
Assessment of genotoxicity and antigenotoxicity of an aqueous
extract of Cleistocalyx nervosum var. paniala in in vitro and in
vivo models. Interdiscip Toxicol. 2012; 5: 201-6.
Inboot W, Taya S, Chailungka A, Meepowpan P, Wongpoomchai R.
Genotoxicity and antigenotoxicity of the methanol extract of
Cleistocalyx nervosum var. paniala seed using a Salmonella
mutation assay and rat liver micronucleus tests. Mol Cell Toxicol.
; 8: 19–24.
Manosroi J, Chankhampan C, Kumguan K, Manosroi W, Manosroi
A. In vitro anti-aging activities of extracts from leaves of Ma
Kiang (Cleistocalyx nervosum var. paniala). Pharm Biol. 2015; 53:
-9.
Phachonpai W, Wattanathorn J. Neuroprotective effect of
Cleistocalyx nervosum var. paniala extract in a rat model of
ischemic stroke. Naresaun Phayao J. 2015; 8: 137-41.
Liang J, Luan Y, Lu B, Zhang H, Luo YN, Ge P. Protection of
ischemic post conditioning against neuronal apoptosis induced
by transient focal ischemia is associated with attenuation of NF-
κB/p65 activation. PLoS One. 2014; 9: e96734.
Cryan JF, Mombereau C, Vassout A. The tail suspension test as a
model for assessing antidepressant activity: Review of
pharmacological and genetic studies in mice. Neurosci Biobehav
Rev. 2005; 29: 571–625.
Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal
model sensitive to antidepressant treatments. Nature. 1977; 266:
–2.
Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric
assay of superoxide dismutase. Indian J Biochem Biophys. 1984;
: 130–2.
Chance B, Maehly AC: Assay of catalase and peroxidases. Meth
Enzymo. 1955; 11: 764-75.
Okhawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animals
tissue by thiobarbituraic acid reaction. Anal Biochem. 1979; 95:
–8.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
measurement with the Folin phenol reagent. Journal Biol Chem.
; 193: 265-75.
Robinson RG, Jorge RE. Post-Stroke Depression: A Review. Am J
Psychiatry. 2016; 173: 221-31.
Du Y, Liang H, Zhang L, Fu F. Pharmacol Biochem Behav. 2017;
: 32-8. Administration of Huperzine A exerts antidepressant-
like activity in a rat model of post- stroke depression.
Kuts R, Melamed I, Shiyntum HN, Frank D, Grinshpun J, Zlotnik A,
et al. A Middle Cerebral Artery Occlusion Technique for Inducing
Post-stroke Depression in Rats. J Vis Exp. 2019; 22: 147.
Tao X, Yang W, Zhu S, Que R, Liu C, Fan T, et al. Models of
poststroke depression and assessments of core depressive
symptoms in rodents: How to choose?, Exp Neurol. 2019; 322:
Takeshita H, Yamamoto K, Nozato S, et al. Modified forelimb grip
strength test detects aging-associated physiological decline in
skeletal muscle function in male mice. Sci Rep. 2017; 7: 42323.
Deuis JR, Dvorakova LS, Vetter I. Methods Used to Evaluate Pain
Behaviors in Rodents. Front Mol Neurosci. 2017; 10: 284.
Willner P. The validity of animal models of depression.
Psychopharmacology (Berl). 1984; 83: 1–16.
Yankelevitch-Yahav R, Franko M, Huly A, Doron R. The forced
swim test as a model of depressive-like behavior. J Vis Exp. 2015;
: 52587.
Michel TM, Frangou S, Thiemeyer D, et al. Evidence for oxidative
stress in the frontal cortex in patients with recurrent depressive
disorder a postmortem study. Psychiatry Res. 2007; 151: 145–50.
Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral
biomarkers in major depression: the potential of inflammatory
and oxidative stress biomarkers. Prog Neuropsychopharmacol
Biol Psychiatry. 2014; 48: 102–11.
Maes M, Galecki P, Chang YS, et al. A review on the oxidative and
nitrosative stress (O&NS) pathways in major depression and
their possible contribution to the (neuro) degenerative processes
in that illness. Prog Neuropsychopharmacol Biol Psychiatry.
; 35: 676–92.
Liu Z, Zhu Z, Zhao J, Ren W, Cai Y, Wang Q, et al.
Malondialdehyde: A novel predictive biomarker for post-stroke
depression. J Affect Disord. 2017; 220: 95-101.
Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT.
Decreased levels of glutathione, the major brain antioxidant, in
post-mortem prefrontal cortex from patients with psychiatric
disorders. Int J Neuropsychopharmacol. 2011; 14:123–30.
Lee SY, Lee SJ, Han C, Patkar AA, Masand PS, Pae CU.
Oxidative/nitrosative stress and antidepressants: targets for
novel antidepressants. Prog Neuropsychopharmacol Biol
Psychiatry. 2013; 1: 224-35.
Adam EK, Doane LD, Zinbarg RE, Mineka S, Craske MG, Griffith
JW. Prospective prediction of major depressive disorder from
cortisol awakening responses in adolescence,”
Psychoneuroendocrinology, 2010; 35: 921–31.
Dienes KA, Hazel NA, Hammen CL. Cortisol secretion in
depressed, and at-risk adults. Psychoneuroendocrinology. 2013;
: 927-40
Refbacks
- There are currently no refbacks.
